Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor HyperinsulinismGlobeNewsWire · Oct 14, 2026
Rezolute, Inc. (NASDAQ:RZLT) Stock Now Rated “Moderate Buy” by Sell-Side AnalystsDefense World · Oct 8, 2026
Rezolute (NASDAQ:RZLT) Stock Sees Unusually High Call Option BuyingDefense World · Oct 5, 2026
Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital HyperinsulinismGlobeNewsWire · Oct 5, 2026
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business UpdateGlobeNewsWire · Sep 24, 2026
Rezolute, Inc. (NASDAQ:RZLT) Receives $9.38 Average Price Target from AnalystsDefense World · Sep 16, 2026Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 24, 2026 | -$0.15 | -$0.20 | Miss |
| May 12, 2026 | -$0.14 | -$0.16 | Miss |
| Feb 12, 2026 | -$0.16 | -$0.22 | Miss |
| Nov 6, 2025 | -$0.27 | -$0.18 | Beat |
| Sep 17, 2025 | -$0.23 | -$0.26 | Miss |
| May 13, 2025 | -$0.22 | -$0.27 | Miss |